Eli Lilly and Company (NYSE:LLY) Trading 5.9% Higher – Here’s What Happened

Eli Lilly and Company (NYSE:LLY) shares shot up 5.9% during trading on Friday . The stock traded as high as $1,185.99 and last traded at $1,193.8510. 531,987 shares traded hands during trading, a decline of 83% from the average session volume of 3,175,585 shares. The stock had previously closed at $1,127.69.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: LLY shares are getting a boost after the European Medicines Agency’s CHMP issued a positive opinion for Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia, potentially expanding the drug’s use across all lines of therapy in the EU. Article: Lilly’s Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
• Positive Sentiment: Investors are also focusing on Lilly’s obesity franchise momentum, including the new Medicare GLP-1 Bridge program that could broaden access to Zepbound and Foundayo starting July 1, which may improve demand visibility. Article: What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
• Positive Sentiment: Recent coverage has highlighted Lilly as a momentum and “clear winner” stock in the weight-loss and diabetes drug race, reinforcing bullish sentiment around its growth story. Article: An Analyst Just Declared Eli Lilly the “Clear Winner” of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo’s Chief Scientist Disagrees. Who’s Right?
• Neutral Sentiment: Lilly also continued drawing attention for pipeline and partnership activity, including work with Abbisko and other biotechs, which supports the long-term story but is less likely to drive the stock intraday. Article: Eli Lilly, Abbisko Expand Drug Hunt With $1.9 Billion Research Pact

Wall Street Analyst Weigh In

A number of equities analysts recently commented on LLY shares. Leerink Partners lifted their price target on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a report on Thursday. Sanford C. Bernstein reissued an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, June 8th. Morgan Stanley restated an “overweight” rating on shares of Eli Lilly and Company in a research report on Friday, June 5th. Wall Street Zen upgraded Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 2nd. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Eli Lilly and Company in a report on Monday. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,235.07.

Eli Lilly and Company Stock Performance

The stock’s 50-day simple moving average is $1,030.27 and its 200-day simple moving average is $1,019.65. The stock has a market cap of $1.13 trillion, a price-to-earnings ratio of 42.85, a price-to-earnings-growth ratio of 1.22 and a beta of 0.53. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.Eli Lilly and Company’s revenue was up 55.5% on a year-over-year basis. During the same quarter last year, the business earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Analysts forecast that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of LLY. Maryland Capital Advisors Inc. acquired a new position in shares of Eli Lilly and Company during the fourth quarter worth $25,000. Osbon Capital Management LLC bought a new stake in Eli Lilly and Company during the 4th quarter worth $25,000. Vermillion & White Wealth Management Group LLC increased its holdings in Eli Lilly and Company by 84.2% in the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after purchasing an additional 16 shares in the last quarter. Basso Capital Management L.P. bought a new position in Eli Lilly and Company in the fourth quarter valued at about $30,000. Finally, 10Elms LLP boosted its stake in shares of Eli Lilly and Company by 33.3% during the third quarter. 10Elms LLP now owns 40 shares of the company’s stock valued at $31,000 after purchasing an additional 10 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.